|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||46.33 - 49.83|
|52 Week Range||23.71 - 63.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.91|
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / U.S. markets jumped Thursday as investor's attention shifted from current geopolitical tensions to the upcoming earnings season. Bank stocks were the top gainers ...
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most ...
MADISON, Wis., April 9, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its first-quarter 2018 financial results after the close of the U.S. financial markets on April 26, 2018. Following the release, company management will host a webcast and conference call at 5 p.m. EDT to discuss financial results and business progress.
EXAS stock is down almost 29% in the same period. Exact is a promising laboratory and research firm in the business of screening patients for colon cancer. Patient compliance for the screening test is at a modest 65% .
Stock Monitor: Biocept Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free earnings report on Exact Sciences Corp. (NASDAQ: EXAS ) ("EXAS"). ...
The 35-percent sell-off in shares of EXACT Sciences Corporation (NASDAQ: EXAS ) offer an attractive entry point, according to BTIG Research. The molecular diagnostics product company's main product is ...
Axogen and Exact Sciences have been big winners in the healthcare sector as they've launched new and attractive products into big addressable markets. Many investors overlooked these opportunities because ...
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / The S&P 500 and the Nasdaq posted their worst daily loss since February 8th on Monday as a sharp decline in Facebook shares triggered a selloff in the technology ...
Exact Sciences' campaign featuring the entertainer and his wife isn't what the market expected.
MADISON, Wis., March 20, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS), the company that developed and commercialized Cologuard®, the only FDA-approved, noninvasive stool DNA-based test for early detection of colorectal cancer, today announced that Mark Stenhouse has been appointed to the new role of president, Cologuard. Stenhouse, vice president, U.S. Immunology at AbbVie, will assume this new position on April 2, 2018. "More than 85 million people are eligible to be screened with Cologuard, and Mark brings the experience and passion to help us reach further into this enormous population," said Kevin Conroy, chairman and CEO of Exact Sciences.
MADISON, Wis., March 19, 2018 /PRNewswire/ -- Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill's recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. "I know firsthand the value of early detection," said Connick.
Exact Sciences Corporation’s (NASDAQ:EXAS): Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. On 31Read More...
Did anyone notice that the PGA golfer wearing the Cologuard hat came close to winning the inaugural Cologuard Classic golf tournament last weekend? If that pro golfer from Madison, Jerry Kelly, had won, it would have scored a unique double victory for the owner of Cologuard, Madison-based Exact Sciences Corp. Exact Sciences (EXAS) secured title sponsorship of the former Tucson Conquistadores Classic PGA Tour Champions event in Tucson, Ariz., late last year as part of its national marketing efforts for the company’s Cologuard product.
NEW YORK, March 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
MADISON, Wis., March 6, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that Paul J. Limburg, M.D., M.P.H., has been appointed the company's co-chief medical officer. Dr. Limburg is a gastroenterologist and a professor of medicine at Mayo Clinic. "We are delighted to welcome Dr. Limburg and believe he'll play a critical leadership role in our mission to eradicate colon cancer," said Kevin T. Conroy, chairman and CEO of Exact Sciences.